单独使用贝瓦西祖马布和结合伊利诺特干治疗复发性质母细胞瘤
Henry S Friedman1, Michael D Prados1, Patrick Y Wen1
1From the Brain Tumor Center, Duke University, Durham, NC; Department of Neurosurgery, University of California, San Francisco, San Francisco; Genetech Inc, South San Francisco; and Department of Neurology, University of California, Los Angeles School of Medicine, Los Angeles, CA; Department of Neurology, Brigham and Women's Hospital and Center for Neuro-Oncology, Dana-Farber Cancer Institute, Boston, MA; Hermelin Brain Tumor Center, Henry Ford Hospital, Detroit, MI; Department of Neurology, University of Virginia, Charlottesville, VA; Department of Neurology, Memorial Sloan-Kettering Cancer Center, New York, NY; Department of Neuro-Oncology, M. D. Anderson Cancer Center, Houston, TX; Division of Neurology, Evanston Northwestern Healthcare, Evanston, IL; Department of Neurology, University of Chicago, Chicago, IL; and University of Utah Hospital, Salt Lake City, UT.
贝瓦西祖马布 (bevacizumab),有或没有 irinotekan,在复发性质母细胞瘤患者中表现出活性. 组合疗法耐受良好,并证明改善了无进展生存率.
科学领域:
- 神经瘤学神经瘤学
- 医学瘤学 医学瘤学
- 临床试验研究临床试验研究
背景情况:
- 质母细胞瘤的复发是一个重大的治疗挑战.
- 对于患有复发性疾病的患者,有效的治疗选择有限.
研究的目的:
- 评估贝瓦齐祖马布单一疗法的疗效和安全性,与贝瓦齐祖马布加上伊利诺特干治疗复发性质母细胞瘤.
- 为了确定无进展的生存率和客观的反应率.
主要方法:
- 第二阶段,多中心,开放标签,非比较性试验.
- 167名患者被随机分配给单独服用贝瓦齐祖马布或与义诺托坎联合服用.
- 主要终点:6个月无进展生存率和客观反应率.
主要成果:
- 6个月无进展生存率为42.6% (单独使用贝瓦西祖马布) 和50.3% (组合).
- 目标响应率分别为28.2%和37.8%.
- 3级以上的不良事件分别发生在46.4%和65.8%的患者中;常见事件包括高血压和.
结论:
- 贝瓦西祖马布,单独或与氨酸合,在复发性质母细胞瘤中具有活性.
- 组合疗法耐受性良好,并显示出有前途的疗效.
相关概念视频
Tumor Immunotherapy
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...


